DSA demand: The company said improved demand in the Discovery and Safety Assessment segment, particularly higher study volume for regulated safety assessment services, supported results.
Manufacturing segment: Better-than-expected performance in the Manufacturing segment, including higher revenue in Microbial Solutions and benefits from divestitures, contributed to results.
RMS weakness: Lower revenue for small research models in North America and research model services weighed on the Research Models and Services segment.
Analyst coverage currently averages "buy", with 12 strong buy or buy ratings, 6 hold ratings, and no sell or strong sell ratings.
The median 12-month price target is $235.00, about 0.4% above the August 4 closing price of $234.12.
The stock recently traded at 20 times the next 12-month earnings, versus 15 times three months ago.
Outlook raised for organic revenue and non-GAAP EPS
Charles River raised its 2026 organic revenue growth guidance to 0.0%-1.0% from (1.5)%-(0.5)%.
The company lifted its 2026 non-GAAP EPS outlook to $11.15-$11.45 from $10.80-$11.30.
Charles River lowered its 2026 GAAP EPS guidance to $3.05-$3.35 from $5.35-$5.85 due to divestiture losses.
CRL•
